Liposomal Form of Erlotinib for Local Inhalation Administration and Efficiency of Its Transport to the Lungs

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216305%3A26310%2F23%3APU147396" target="_blank" >RIV/00216305:26310/23:PU147396 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/68081731:_____/23:00571764

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S0378517323001151" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0378517323001151</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ijpharm.2023.122695" target="_blank" >10.1016/j.ijpharm.2023.122695</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Liposomal Form of Erlotinib for Local Inhalation Administration and Efficiency of Its Transport to the Lungs

Popis výsledku v původním jazyce

This contribution is focused on the preparation of a liposomal drug delivery system of erlotinib resisting the nebulization process that could be used for local treatment of non-small-cell lung cancer. Liposomes with different compositions were formulated to reveal their influence on the encapsulation efficiency of erlotinib. An encapsulation efficiency higher than 98 % was achieved for all vesicles containing phosphatidic acid (d ≈ 100 nm , ζ = – 43 mV) even in the presence of polyethylene glycol (d ≈ 150 nm, ζ = – 17 mV) which decreased this value in all other formulas. The three most promising formulations were nebulized by two air-jet and two vibrating mesh nebulizers, and the aerosol deposition in lungs was calculated by tools of computational fluid and particle mechanics. According to the numerical simulations and measurements of liposomal stability, air-jet nebulizers generated larger portion of the aerosol able to penetrate deeper into the lungs, but the delivery is likely to be more efficient when the formulation is administered by Aerogen Solo vibrating mesh nebulizer because of a higher portion of intact vesicles after the nebulization. The leakage of encapsulated drug from liposomes nebulized by this nebulizer was lower than 2 % for all chosen vesicles.

Název v anglickém jazyce

Liposomal Form of Erlotinib for Local Inhalation Administration and Efficiency of Its Transport to the Lungs

Popis výsledku anglicky

This contribution is focused on the preparation of a liposomal drug delivery system of erlotinib resisting the nebulization process that could be used for local treatment of non-small-cell lung cancer. Liposomes with different compositions were formulated to reveal their influence on the encapsulation efficiency of erlotinib. An encapsulation efficiency higher than 98 % was achieved for all vesicles containing phosphatidic acid (d ≈ 100 nm , ζ = – 43 mV) even in the presence of polyethylene glycol (d ≈ 150 nm, ζ = – 17 mV) which decreased this value in all other formulas. The three most promising formulations were nebulized by two air-jet and two vibrating mesh nebulizers, and the aerosol deposition in lungs was calculated by tools of computational fluid and particle mechanics. According to the numerical simulations and measurements of liposomal stability, air-jet nebulizers generated larger portion of the aerosol able to penetrate deeper into the lungs, but the delivery is likely to be more efficient when the formulation is administered by Aerogen Solo vibrating mesh nebulizer because of a higher portion of intact vesicles after the nebulization. The leakage of encapsulated drug from liposomes nebulized by this nebulizer was lower than 2 % for all chosen vesicles.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10403 - Physical chemistry

Projekt

<a href="/cs/project/GA20-27653S" target="_blank" >GA20-27653S: Vliv vývoje plic u novorozenců a dětí na charakteristiky proudění a depozici aerosolů – výpočtové modelování a experimentální validace</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

INTERNATIONAL JOURNAL OF PHARMACEUTICS

ISSN

0378-5173

e-ISSN

1873-3476

Svazek periodika

634

Číslo periodika v rámci svazku

march

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

12

Strana od-do

1-12

Kód UT WoS článku

000944796400001

EID výsledku v databázi Scopus

—